Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening

Botulinum neurotoxin serotype A (BoNT/A) is the most lethal toxin among the Tier 1 Select Agents. Development of potent and selective small molecule inhibitors against BoNT/A zinc metalloprotease remains a challenging problem due to its exceptionally large substrate binding surface and conformational plasticity. The exosites of the catalytic domain of BoNT/A are intriguing alternative sites for small molecule intervention, but their suitability for inhibitor design remains largely unexplored. In this study, we employed two recently identified exosite inhibitors, D-chicoric acid and lomofungin, to probe the structural features of the exosites and molecular mechanisms of synergistic inhibition. The results showed that D-chicoric acid favors binding at the α-exosite, whereas lomofungin preferentially binds at the β-exosite by mimicking the substrate β-sheet binding interaction. Molecular dynamics simulations and binding interaction analysis of the exosite inhibitors with BoNT/A revealed key elements and hotspots that likely contribute to the inhibitor binding and synergistic inhibition. Finally, we performed database virtual screening for novel inhibitors of BoNT/A targeting the exosites. Hits C1 and C2 showed non-competitive inhibition and likely target the α- and β-exosites, respectively. The identified exosite inhibitors may provide novel candidates for structure-based development of therapeutics against BoNT/A intoxication.

[1]  G. Schiavo,et al.  Structure and function of tetanus and botulinum neurotoxins , 1995, Quarterly Reviews of Biophysics.

[2]  S. Tzipori,et al.  Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents , 2009, Infection and Immunity.

[3]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[4]  Y. Pang,et al.  Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. , 2006, Bioorganic & medicinal chemistry.

[5]  S. Swaminathan,et al.  Structure- and Substrate-based Inhibitor Design for Clostridium botulinum Neurotoxin Serotype A* , 2008, Journal of Biological Chemistry.

[6]  Leonard A. Smith,et al.  Botulinum neurotoxin vaccines: past, present, and future. , 2007, Critical reviews in immunology.

[7]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[8]  R. Stevens,et al.  A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. , 2010, Journal of molecular biology.

[9]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[10]  R. Stevens,et al.  Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. , 2011, Biochemistry.

[11]  Leonard A. Smith,et al.  Identification and Biochemical Characterization of Small-Molecule Inhibitors of Clostridium botulinum Neurotoxin Serotype A , 2009, Antimicrobial Agents and Chemotherapy.

[12]  Axel T. Brunger,et al.  Substrate recognition strategy for botulinum neurotoxin serotype A , 2004, Nature.

[13]  R. Stevens,et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity , 1998, Nature Structural Biology.

[14]  J. Barbieri,et al.  Mechanism of Substrate Recognition by Botulinum Neurotoxin Serotype A* , 2007, Journal of Biological Chemistry.

[15]  K. Janda,et al.  Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. , 2010, Journal of the American Chemical Society.

[16]  J. Alves,et al.  Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. , 2002, Biochemistry.

[17]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[18]  Rick Gussio,et al.  Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. , 2003, Biochemical and biophysical research communications.

[19]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[20]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[21]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[22]  S. Swaminathan Molecular structures and functional relationships in clostridial neurotoxins , 2011, The FEBS journal.

[23]  Richa Rawat,et al.  Substrate Binding Mode and Its Implication on Drug Design for Botulinum Neurotoxin A , 2008, PLoS pathogens.

[24]  Y. Pang,et al.  Small Molecules Showing Significant Protection of Mice against Botulinum Neurotoxin Serotype A , 2010, PloS one.

[25]  L. Smith,et al.  Development of vaccines for prevention of botulism. , 2000, Biochimie.

[26]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[27]  K. Janda,et al.  Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. , 2010, ACS medicinal chemistry letters.

[28]  Kim D Janda,et al.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. , 2007, Chemistry & biology.

[29]  Matthew A. Lardy,et al.  The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft. , 2013, ACS medicinal chemistry letters.

[30]  K. Janda,et al.  Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[31]  D. Zaharevitz,et al.  Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. , 2005, Bioorganic & medicinal chemistry.

[32]  Leonard A. Smith,et al.  Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. , 2009, Archives of biochemistry and biophysics.

[33]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[34]  Sina Bavari,et al.  The evolving field of biodefence: therapeutic developments and diagnostics , 2005, Nature Reviews Drug Discovery.

[35]  Jaques Reifman,et al.  DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0 , 2008, Chemistry Central journal.

[36]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[37]  A. Brunger,et al.  Receptor and substrate interactions of clostridial neurotoxins. , 2009, Toxicon : official journal of the International Society on Toxinology.

[38]  Leonard A. Smith,et al.  Identification of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin Important for Substrate Recognition and Catalytic Activity , 2008, The protein journal.